304840 — Peoplebio Balance Sheet
0.000.00%
- KR₩71bn
- KR₩71bn
- KR₩4bn
Annual balance sheet for Peoplebio, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | PROSPECTUS | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts | Annual Audited Accounts |
Standards: | IFRS | IFRS | IFRS | IFRS | IFRS |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 3,016 | 9,365 | 38,810 | 22,543 | 5,244 |
Net Total Accounts Receivable | |||||
Net Total Receivables | 521 | 288 | 303 | 1,768 | 4,045 |
Total Inventory | |||||
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 3,736 | 10,099 | 40,145 | 29,341 | 14,810 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 486 | 384 | 2,289 | 3,672 | 3,550 |
Net Goodwill | |||||
Net Intangible Assets | |||||
Long Term Investments | |||||
Other Long Term Assets | |||||
Total Assets | 4,357 | 10,655 | 51,348 | 42,316 | 27,580 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 372 | 507 | 29,266 | 32,836 | 3,533 |
Long Term Debt | |||||
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Minority Interest | |||||
Total Other Liabilities | |||||
Total Funded Status | |||||
Total Liabilities | 1,655 | 1,827 | 34,432 | 38,237 | 8,409 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
ESOP Debt Guarantee | |||||
Other Equity | |||||
Total Equity | 2,702 | 8,828 | 16,915 | 4,079 | 19,171 |
Total Liabilities & Shareholders' Equity | 4,357 | 10,655 | 51,348 | 42,316 | 27,580 |
Total Common Shares Outstanding |